

## Disclosures

### Personal Commercial (27)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b><i>Self</i></b>			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Alnylam	Research/Research Grants	Significant (>= \$5,000)	<i>Other</i>
Alnylam	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Avidity Biopharma	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Axon Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Baim Clinical Research Institute	Other - <i>Adjudicator for CEC</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
Bayer Healthcare Pharmaceuticals	Research/Research Grants	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
biofourmis	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
endotronix	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
GlaxoSmithKline	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Other</i>
Medpace	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
New Amsterdam	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Parexel	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Pfizer Inc	Research/Research Grants <i>‡ GARDEN TIMI-75</i>	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
Regeneron	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
River2Renal	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
scPharma	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Teva	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
TIMI Study Group	Other - <i>Adjudication for CEC</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
Volta medical	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<b>Self</b>				
2019	Cardiomyopathy	Defendant	Failure to diagnose and treat hemochromatosis involving the heart	Modest (< \$5,000)
2018	Out of Hospital Cardiac Arrest	Plaintiff	Failure to defibrillate patient with available AED during out of hospital arrest	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 8/26/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/26/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### Embargo | Signed on 8/26/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### On-Going Obligation Agreement | Signed on 8/26/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.